Septerna (NASDAQ:SEPN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Septerna (NASDAQ:SEPN) had its price target lifted by research analysts at JPMorgan Chase & Co. from $38.00 to $48.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 9.35% from the stock’s current price.

Several other brokerages have also commented on SEPN. HC Wainwright upped their price objective on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Truist Financial lifted their target price on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Stifel Nicolaus set a $49.00 target price on Septerna in a research report on Tuesday, August 11th. Raymond James Financial restated a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. Finally, Wells Fargo & Company raised their price target on Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $52.44.

Septerna Trading Up 0.2%

SEPN traded up $0.10 on Wednesday, hitting $43.90. The company had a trading volume of 155,599 shares, compared to its average volume of 362,171. The firm has a market cap of $2.05 billion, a P/E ratio of -81.21 and a beta of 2.29. Septerna has a 1 year low of $10.74 and a 1 year high of $51.10. The company’s fifty day moving average price is $36.37 and its 200 day moving average price is $29.94.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. The company had revenue of $26.75 million for the quarter, compared to analysts’ expectations of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. On average, analysts predict that Septerna will post -1.36 earnings per share for the current year.

Insider Buying and Selling at Septerna

In other news, insider Samira Shaikhly sold 2,178 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the completion of the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $27,897.74. The trade was a 73.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Daniel D. Long sold 3,334 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $34.47, for a total transaction of $114,922.98. Following the sale, the senior vice president owned 96,412 shares in the company, valued at $3,323,321.64. The trade was a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 72,828 shares of company stock valued at $2,684,314 in the last quarter. Corporate insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG increased its holdings in Septerna by 5.3% in the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after buying an additional 744 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in Septerna during the 4th quarter worth about $35,000. JPMorgan Chase & Co. boosted its position in shares of Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after acquiring an additional 1,315 shares in the last quarter. PharVision Advisers LLC boosted its position in shares of Septerna by 17.5% during the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after acquiring an additional 1,780 shares in the last quarter. Finally, Nuveen LLC increased its holdings in shares of Septerna by 7.7% in the 4th quarter. Nuveen LLC now owns 25,798 shares of the company’s stock valued at $719,000 after acquiring an additional 1,837 shares during the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.